In the primary cohort, most patients were female, postmenopausal, or white, and many had an invasive ductal carcinoma, a grade 3 tumor, estrogen receptor–positive disease, or stage II disease. This evidence concerns the gene ESR1 and invasive ductal breast carcinoma.